Compare TransMedics Group Inc (TMDX) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Vanguard Total World Stock Index Fund ETF — how do they compare? TransMedics Group Inc trades at $73.5 (market cap $2.54B), while Vanguard Total World Stock Index Fund ETF trades at $156.36. The key difference: Vanguard Total World Stock Index Fund ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| TMDX | VT | |
|---|---|---|
Market Cap | $2.54B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $150.42 | $159.35 |
52-Week Low | $61.99 | $128.41 |
Enterprise Value | $2.94B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics (TMDX) is trading at $73.47, down 0.69% on the day, amid a mixed technical and fundamental backdrop. The stock shows neutral technical signals with support near $72 and resistance at $75, while fundamentals are strong with a trailing P/E of 16.81 and robust profitability metrics like a 27.04% net income margin. Recent earnings saw a Q1 2026 miss but beats in prior quarters, and the company is expanding in Europe through strategic investments.
The outlook is cautiously optimistic with a consensus price target of $108.71 implying significant upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion costs and competitive threats, but the company's organ transplant logistics network offers a durable competitive advantage for long-term growth.
Vanguard Total World Stock ETF (VT) trades at $154.29, down 0.32% on the day, with technical indicators showing a bearish bias despite neutral oscillators. The ETF provides diversified global equity exposure with over 10,000 stocks across developed and emerging markets. Recent news highlights institutional interest, with Alta Advisers Ltd increasing its position by 18.5% in Q1 2026 (SEC filing, 2026-07-21).
VT offers broad global diversification with a low 0.06% expense ratio, appealing for long-term investors seeking worldwide market exposure. Key risks include global economic volatility and currency fluctuations. The bearish technical signals suggest near-term pressure, but the fund's comprehensive coverage provides stability for portfolio construction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
